Neuphoria Therapeutics (NEUP) stock was down 67% in recent Tuesday premarket activity after the company said overnight that a phase 3 trial of BNC210 for the acute treatment of social anxiety disorder did not meet its primary endpoint.
Galapagos (GLPG) shares were down 13% after the company said it decided to wind down its cell therapy operations.
Newmont (NEM) stock was 4% lower, erasing Monday's gain.
PulteGroup (PHM) shares were down 2.1% after the company posted lower Q3 earnings and revenue.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments